ADPT Adaptive Biotechnologies Corp

Price (delayed)

$6.91

Market cap

$997.19M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.37

Enterprise value

$1.13B

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Adaptive Biotechnologies believes the ...

Highlights
The quick ratio has surged by 56% year-on-year and by 7% since the previous quarter
The revenue has grown by 19% YoY
The gross profit has grown by 19% year-on-year but it has declined by 5% since the previous quarter
ADPT's debt has surged by 105% year-on-year
ADPT's equity is down by 23% year-on-year and by 9% since the previous quarter

Key stats

What are the main financial stats of ADPT
Market
Shares outstanding
144.31M
Market cap
$997.19M
Enterprise value
$1.13B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.33
Price to sales (P/S)
5.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.15
Earnings
Revenue
$184.34M
EBIT
-$187.39M
EBITDA
-$158.86M
Free cash flow
-$194.84M
Per share
EPS
-$1.37
Free cash flow per share
-$1.36
Book value per share
$2.96
Revenue per share
$1.28
TBVPS
$4.64
Balance sheet
Total assets
$791.46M
Total liabilities
$367.51M
Debt
$232.79M
Equity
$424.02M
Working capital
$411.23M
Liquidity
Debt to equity
0.55
Current ratio
5.56
Quick ratio
5.26
Net debt/EBITDA
-0.86
Margins
EBITDA margin
-86.2%
Gross margin
65.6%
Net margin
-105.9%
Operating margin
-105.4%
Efficiency
Return on assets
-23.4%
Return on equity
-41.2%
Return on invested capital
-27.3%
Return on capital employed
-26.7%
Return on sales
-101.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ADPT stock price

How has the Adaptive Biotechnologies stock price performed over time
Intraday
1.62%
1 week
10.03%
1 month
-5.67%
1 year
-8.72%
YTD
-9.55%
QTD
-21.74%

Financial performance

How have Adaptive Biotechnologies's revenue and profit performed over time
Revenue
$184.34M
Gross profit
$120.94M
Operating income
-$194.31M
Net income
-$195.15M
Gross margin
65.6%
Net margin
-105.9%
ADPT's net margin is up by 29% year-on-year
Adaptive Biotechnologies's operating margin has increased by 29% YoY and by 2.4% QoQ
The gross profit has grown by 19% year-on-year but it has declined by 5% since the previous quarter
The revenue has grown by 19% YoY

Growth

What is Adaptive Biotechnologies's growth rate over time

Valuation

What is Adaptive Biotechnologies stock price valuation
P/E
N/A
P/B
2.33
P/S
5.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.15
ADPT's EPS is up by 16% year-on-year and by 2.1% since the previous quarter
ADPT's equity is down by 23% year-on-year and by 9% since the previous quarter
ADPT's P/B is 2.9% below its last 4 quarters average of 2.4
ADPT's price to sales (P/S) is 84% lower than its 5-year quarterly average of 32.8 and 17% lower than its last 4 quarters average of 6.5
The revenue has grown by 19% YoY

Efficiency

How efficient is Adaptive Biotechnologies business performance
ADPT's return on sales is up by 31% year-on-year and by 3.8% since the previous quarter
The ROIC has grown by 19% YoY and by 8% from the previous quarter
The ROE has decreased by 12% YoY and by 4% QoQ
Adaptive Biotechnologies's ROA has increased by 2.9% YoY

Dividends

What is ADPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ADPT.

Financial health

How did Adaptive Biotechnologies financials performed over time
The total assets is 115% more than the total liabilities
The quick ratio has surged by 56% year-on-year and by 7% since the previous quarter
The current ratio has soared by 53% YoY and by 9% from the previous quarter
ADPT's debt is 45% smaller than its equity
ADPT's debt to equity has surged by 162% year-on-year and by 10% since the previous quarter
ADPT's debt has surged by 105% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.